CME Net Worth
CME Net Worth Breakdown | CME |
CME Net Worth Analysis
CME's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CME's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CME's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CME's net worth analysis. One common approach is to calculate CME's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CME's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CME's net worth. This approach calculates the present value of CME's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CME's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CME's net worth. This involves comparing CME's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CME's net worth relative to its peers.
Enterprise Value |
|
To determine if CME is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CME's net worth research are outlined below:
| CME Group has a strong financial position based on the latest SEC filings | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| On 25th of September 2024 CME paid $ 1.15 per share dividend to its current shareholders | |
| Latest headline from cbsnews.com: How far have mortgage interest rates fallen in 2024 |
CME Quarterly Good Will |
|
CME uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CME Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CME's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know CME's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CME is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CME Group backward and forwards among themselves. CME's institutional investor refers to the entity that pools money to purchase CME's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fidelity International Ltd | 2024-06-30 | 3.9 M | Northern Trust Corp | 2024-09-30 | 3.5 M | Vontobel Holding Ltd. | 2024-06-30 | 3.5 M | Fiera Capital Corporation | 2024-06-30 | 3.3 M | Guardcap Asset Management Limited | 2024-09-30 | 3.3 M | Royal Bank Of Canada | 2024-06-30 | 3.2 M | Mitsubishi Ufj Asset Management Co.,ltd | 2024-09-30 | 3 M | Raymond James & Associates | 2024-09-30 | 2.9 M | Legal & General Group Plc | 2024-06-30 | 2.8 M | Vanguard Group Inc | 2024-09-30 | 33.9 M | Blackrock Inc | 2024-06-30 | 25.7 M |
Follow CME's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 81.64 B.Market Cap |
|
Project CME's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.06 | |
| Return On Capital Employed | 0.09 | 0.17 | |
| Return On Assets | 0.02 | 0.03 | |
| Return On Equity | 0.12 | 0.12 |
When accessing CME's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CME's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CME's profitability and make more informed investment decisions.
Please note, the presentation of CME's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CME's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CME's management manipulating its earnings.
Evaluate CME's management efficiency
CME Group has Return on Asset of 0.0184 % which means that on every $100 spent on assets, it made $0.0184 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.123 %, implying that it generated $0.123 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Equity is forecasted to decline to 0.12. At present, CME's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 95.9 B, whereas Other Assets are forecasted to decline to about 127.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 74.47 | 38.69 | |
| Tangible Book Value Per Share | (11.09) | (11.65) | |
| Enterprise Value Over EBITDA | 20.22 | 14.21 | |
| Price Book Value Ratio | 2.83 | 3.80 | |
| Enterprise Value Multiple | 20.22 | 14.21 | |
| Price Fair Value | 2.83 | 3.80 | |
| Enterprise Value | 60.2 B | 63.3 B |
CME Group has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 13.7581 | Revenue 6 B | Quarterly Revenue Growth 0.185 | Revenue Per Share 16.795 | Return On Equity 0.123 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CME insiders, such as employees or executives, is commonly permitted as long as it does not rely on CME's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CME insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mccourt Timothy Francis over three months ago Disposition of tradable shares by Mccourt Timothy Francis of CME at 217.5 subject to Rule 16b-3 | ||
Julie Winkler over a year ago Acquisition by Julie Winkler of 3808 shares of CME subject to Rule 16b-3 | ||
Julie Winkler over a year ago Payment of 1513 shares by Julie Winkler of CME subject to Rule 16b-3 |
CME Corporate Filings
F4 | 12th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 22nd of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
CME Earnings per Share Projection vs Actual
CME Corporate Directors
| Hilda Piell | Chief Human Resource Officer, Senior Managing Director | Profile | |
| Jack Tobin | Chief Accounting Officer, Managing Director | Profile | |
| Derek Sammann | Senior Managing Director - Financial Products and Services | Profile | |
| Julie Winkler | Senior Managing Director - Research and Product Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Financial Exchanges & Data space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.214 | Dividend Share 4.55 | Earnings Share 9.51 | Revenue Per Share 16.795 | Quarterly Revenue Growth 0.185 |
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.